Pharvaris N.V. (PHVS)
Nasdaq: PHVS · Pharmaceutical Preparations · Leiden, NL · filing with the SEC since 2020
Who owns Pharvaris N.V.
As filed with the SECHolders of 5% or more
2
General Atlantic, L.P. holds 7.6% of Ordinary shares, par value Euro 0.12 per share, as its SCHEDULE 13G/A filed Aug 14, 2026 says.
Directors and officers
13
report now, of 13 people on the record since 2026. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 2 named at left.
Holders of 5% or moreshare of the class, as filed
General Atlantic, L.P.
SCHEDULE 13G/A · filed Aug 14, 2026 · Ordinary shares, par value Euro 0.12 per share
Viking Global Investors LP
SCHEDULE 13G/A · filed May 15, 2026 · Ordinary Shares, par value Euro 0.12 per share
LSP V Cooperatieve U.A.
SCHEDULE 13G/A · filed Jul 31, 2026 · Ordinary Shares, par value Euro 0.12 per share · reported falling below 5%
Venrock Healthcare Capital Partners III, L.P.
SCHEDULE 13G/A · filed Aug 14, 2025 · Ordinary shares, par value EURO0.12 per share · reported falling below 5%
Bain Capital Life Sciences Fund, L.P.
SCHEDULE 13G/A · filed Feb 17, 2026 · Ordinary Shares, Euro 0.12 par value per share · reported falling below 5%, from 3% in Nov 14, 2025
What PHVS reports owning in othersstakes of 5% or more, and other ties
5 subsidiaries in 3 countries, from the list filed with the 20-F filed Apr 2, 2026.
Insider tradesForm 4
71sales
0purchases
53sales on a scheduled plan
11people selling
$33.0Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 12, 2025 to Nov 12, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 12, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window11 of 13 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Schikan Johannes Gerardus Christiaan Petrus | director | 10 | $9.7M | 8 | 0 | $0 |
| Lu Peng | President | 13 | $6.9M | 12 | 0 | $0 |
| Lesage Anne | Chief Early Development | 19 | $6.7M | 18 | 0 | $0 |
| Bjork Elisabeth | director | 2 | $2.3M | 1 | 0 | $0 |
| Abele Stefan Andreas | Chief Technical Ops Officer | 3 | $2.0M | 0 | 0 | $0 |
| Glassman Robert | director | 5 | $1.5M | 2 | 0 | $0 |
| Souverijns Wim | Chief Commercial Officer | 3 | $1.3M | 3 | 0 | $0 |
| Modig Berndt | Chief Executive Officer | 9 | $1.1M | 9 | 0 | $0 |
| Monges Viviane | director | 2 | $700,000 | 0 | 0 | $0 |
| Nassif David W. | CFO / CLO | 2 | $500,000 | 0 | 0 | $0 |
| Nijdam Anna | Principal Accounting Officer | 3 | $300,000 | 0 | 0 | $0 |